Top

Clinical Reviews in Allergy & Immunology

Published in:

01-06-2012

Cutting Edge Issues in Autoimmune Gastritis

Authors: Ban-Hock Toh, James Chan, Tin Kyaw, Frank Alderuccio

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2012

Abstract

Autoimmune gastritis is the outcome of a pathological CD4 T cell-mediated autoimmune response directed against the gastric H/K-ATPase. Silent initially, the gastric lesion becomes manifest in humans by the development of megaloblastic pernicious anemia arising from vitamin B12 deficiency. Cutting edge issues in this disease relate to its epidemiology, immunogenetics, a role for Helicobacter pylori as an infective trigger through molecular mimicry, its immunopathogenesis, associated organ-specific autoimmune diseases, laboratory diagnosis, and approaches to curative therapy.

Toh BH, van Driel IR, Gleeson PA (1997) Pernicious anemia. N Engl J Med 337(20):1441–1448PubMedCrossRef

Field J, Biondo MA, Murphy K, Alderuccio F, Toh BH (2005) Experimental autoimmune gastritis: mouse models of human organ-specific autoimmune disease. Int Rev Immunol 24(1–2):93–110PubMedCrossRef

Alderuccio F, Sentry JW, Marshall AC, Biondo M, Toh BH (2002) Animal models of human disease: experimental autoimmune gastritis—a model for autoimmune gastritis and pernicious anemia. Clin Immunol 102(1):48–58PubMedCrossRef

Biondo M, Nasa Z, Marshall A, Toh BH, Alderuccio F (2001) Local transgenic expression of granulocyte macrophage-colony stimulating factor initiates autoimmunity. J Immunol 166(3):2090–2099PubMed

Toh BH, Sentry JW, Alderuccio F (2000) The causative H+/K + ATPase antigen in the pathogenesis of autoimmune gastritis. Immunol Today 21(7):348–354PubMedCrossRef

Bergman MP, Amedei A, D'Elios MM, Azzurri A, Benagiano M, Tamburini C, van der Zee R, Vandenbroucke-Grauls CM, Appelmelk BJ, Del Prete G (2003) Characterization of H+, K + −ATPase T cell epitopes in human autoimmune gastritis. Eur J Immunol 33(2):539–545PubMedCrossRef

Adamu MA, Weck MN, Gao L, Brenner H (2010) Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. Eur J Epidemiol 25(7):439–448PubMedCrossRef

Lombardo L, Leto R, Molinaro G, Migliardi M, Ravarino N, Rocca R, Torchio B (2010) Prevalence of atrophic gastritis in dyspeptic patients in Piedmont. A survey using the GastroPanel test. Clin Chem Lab Med (in press)

Telaranta-Keerie A, Kara R, Paloheimo L, Härkönen M, Sipponen P (2010) Prevalence ofundiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints. Scand J Gastroenterol (in press)

10.

Ang DK, Brodnicki TC, Jordan MA, Wilson WE, Silveira P, Gliddon BL, Baxter AG, van Driel IR (2007) Two genetic loci independently confer susceptibility to autoimmune gastritis. Int Immunol 19(9):1135–1144PubMedCrossRef

11.

Lahner E, Spoletini M, Buzzetti R, Corleto VD, Vannella L, Petrone A, Annibale B (2010) HLA-DRB1*03 and DRB1*04 are associated with atrophic gastritis in an Italian population. Dig Liver Dis (in press)

12.

Oksanen AM, Haimila KE, Rautelin HI, Partanen JA (2010) Immunogenetic characteristics of patients with autoimmune gastritis. World J Gastroenterol 16(3):354–358PubMedCrossRef

13.

Amedei A, Bergman MP, Appelmelk BJ, Azzurri A, Benagiano M, Tamburini C, van der Zee R, Telford JL, Vandenbroucke-Grauls CM, D’Elios MM, Del Prete G (2003) Molecular mimicry between Helicobacter pylori antigens and H+, K + –adenosine triphosphatase in human gastric autoimmunity. J Exp Med 198(8):1147–1156PubMedCrossRef

14.

Bergman MP, Vandenbroucke-Grauls CM, Appelmelk BJ, D’Elios MM, Amedei A, Azzurri A, Benagiano M, Del Prete G (2005) The story so far: helicobacter pylori and gastric autoimmunity. Int Rev Immunol 24(1–2):63–91PubMedCrossRef

15.

Veijola LI, Oksanen AM, Sipponen PI, Rautelin HI (2010) Association of autoimmune type atrophic corpus gastritis with Helicobacter pylori infection. World J Gastroenterol 16(1):83–88PubMed

16.

Gao L, Weck MN, Nieters A, Brenner H (2009) Inverse association between a pro-inflammatory genetic profile and Helicobacter pylori seropositivity among patients with chronic atrophic gastritis: enhanced elimination of the infection during disease progression? Eur J Cancer 45(16):2860–2866PubMedCrossRef

17.

Weck MN, Gao L, Brenner H (2009) Helicobacter pylori infection and chronic atrophic gastritis: associations according to severity of disease. Epidemiology 20(4):569–574PubMedCrossRef

18.

Alderuccio F, Toh BH, Tan SS, Gleeson PA, van Driel IR (1993) An autoimmune disease with multiple molecular targets abrogated by the transgenic expression of a single autoantigen in the thymus. J Exp Med 178(2):419–426PubMedCrossRef

19.

Klein L, Kyewski B (2000) “Promiscuous” expression of tissue antigens in the thymus: a key to T-cell tolerance and autoimmunity? J Mol Med 78(9):483–494, ReviewPubMedCrossRef

20.

Gardner JM, Devoss JJ, Friedman RS, Wong DJ, Tan YX, Zhou X, Johannes KP, Su MA, Chang HY, Krummel MF, Anderson MS (2008) Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 321(5890):843–847PubMedCrossRef

21.

Gotter J, Brors B, Hergenhahn M, Kyewski B (2004) Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 199(2):155–166PubMedCrossRef

22.

Macedo C, Evangelista AF, Magalhães DA, Fornari TA, Linhares LL, Junta CM, Silva GL, Sakamoto-Hojo ET, Donadi EA, Savino W, Passos GA (2009) Evidence for a network transcriptional control of promiscuous gene expression in medullary thymic epithelial cells. Mol Immunol 46(16):3240–3244PubMedCrossRef

23.

Irla M, Hollander G, Reith W (2010) Control of central self-tolerance induction by autoreactive CD4+ thymocytes. Trends Immunol 31(2):71–79PubMedCrossRef

24.

Alderuccio F, Gleeson PA, Berzins SP, Martin M, Van Driel IR, Toh BH (1997) Expression of the gastric H/K-ATPase alpha-subunit in the thymus may explain the dominant role of the beta-subunit in the pathogenesis of autoimmune gastritis. Autoimmunity 25(3):167–175PubMedCrossRef

25.

Read S, Hogan TV, Zwar TD, Gleeson PA, van Driel IR (2007) Prevention of autoimmune gastritis in mice requires extra-thymic T-cell deletion and suppression by regulatory T cells. Gastroenterology 133(2):547–558PubMedCrossRef

26.

Fukuma K, Sakaguchi S, Kuribayashi K, Chen WL, Morishita R, Sekita K, Uchino H, Masuda T (1988) Immunologic and clinical studies on murine experimental autoimmune gastritis induced by neonatal thymectomy. Gastroenterology 94(2):274–283PubMed

27.

Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T (1985) Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 161(1):72–87PubMedCrossRef

28.

Suri-Payer E, Amar AZ, Thornton AM, Shevach EM (1998) CD4 + CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 160(3):1212–1218PubMed

29.

DiPaolo RJ, Glass DD, Bijwaard KE, Shevach EM (2005) CD4 + CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J Immunol 175(11):7135–7142PubMed

30.

DiPaolo RJ, Brinster C, Davidson TS, Andersson J, Glass D, Shevach EM (2007) Autoantigen-specific TGFbeta-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J Immunol 179(7):4685–4693PubMed

31.

Huter EN, Stummvoll GH, DiPaolo RJ, Glass DD, Shevach EM (2009) Pre-differentiated Th1 and Th17 effector T cells in autoimmune gastritis: Ag-specific regulatory T cells are more potent suppressors than polyclonal regulatory T cells. Int Immunopharmacol 9(5):540–545PubMedCrossRef

32.

Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O’Shea JJ, Shevach EM (2008) CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 205(9):1975–1981PubMedCrossRef

33.

Scheinecker C, McHugh R, Shevach EM, Germain RN (2002) Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 196(8):1079–1090PubMedCrossRef

34.

Barrett SP, Riordon A, Toh BH, Gleeson PA, van Driel IR (2000) Homing and adhesion molecules in autoimmune gastritis. J Leukoc Biol 67(2):169–173PubMed

35.

Suri-Payer E, Amar AZ, McHugh R, Natarajan K, Margulies DH, Shevach EM (1999) Post-thymectomy autoimmune gastritis: fine specificity and pathogenicity of anti-H/K ATPase-reactive T cells. Eur J Immunol 29(2):669–677PubMedCrossRef

36.

McHugh RS, Shevach EM, Margulies DH, Natarajan K (2001) A T cell receptor transgenic model of severe, spontaneous organ-specific autoimmunity. Eur J Immunol 31(7):2094–2103PubMedCrossRef

37.

Candon S, McHugh RS, Foucras G, Natarajan K, Shevach EM, Margulies DH (2004) Spontaneous organ-specific Th2-mediated autoimmunity in TCR transgenic mice. J Immunol 172(5):2917–2924PubMed

38.

Stummvoll GH, DiPaolo RJ, Huter EN, Davidson TS, Glass D, Ward JM, Shevach EM (2008) Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J Immunol 181(3):1908–1916PubMed

39.

Lam-Tse WK, Batstra MR, Koeleman BP, Roep BO, Bruining MG, Aanstoot HJ, Drexhage HA (2003) The association between autoimmune thyroiditis, autoimmune gastritis and type 1 diabetes. Pediatr Endocrinol Rev 1(1):22–37PubMed

40.

Tsirogianni A, Pipi E, Soufleros K (2009) Specificity of islet cell autoantibodies and coexistence with other organ specific autoantibodies in type 1 diabetes mellitus. Autoimmun Rev 8(8):687–691PubMedCrossRef

41.

Lahner E, Centanni M, Agnello G, Gargano L, Vannella L, Iannoni C, Delle Fave G, Annibale B (2008) Occurrence and risk factors for autoimmune thyroid disease in patients with atrophic body gastritis. Am J Med 121(2):136–141PubMedCrossRef

42.

Ness-Abramof R, Nabriski DA, Braverman LE, Shilo L, Weiss E, Reshef T, Shapiro MS, Shenkman L (2006) Prevalence and evaluation of B12 deficiency in patients with autoimmune thyroid disease. Am J Med Sci 332(3):119–122PubMedCrossRef

43.

Burman P, Kämpe O, Kraaz W, Lööf L, Smolka A, Karlsson A, Karlsson-Parra A (1992) A study of autoimmune gastritis in the postpartum period and at a 5-year follow-up. Gastroenterology 103(3):934–942PubMed

44.

Hershko C, Ronson A, Souroujon M, Maschler I, Heyd J, Patz J (2006) Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood 107(4):1673–1679PubMedCrossRef

45.

Hershko C, Patz J, Ronson A (2007) The anemia of achylia gastrica revisited. Blood Cells Mol Dis 39(2):178–183PubMedCrossRef

46.

Zauli D, Tosti A, Biasco G, Miserocchi F, Patrizi A, Azzaroni D, Andriani G, Di Febo G, Callegari C (1986) Prevalence of autoimmune atrophic gastritis in vitiligo. Digestion 34(3):169–172PubMedCrossRef

47.

De Block CE, De Leeuw IH, Van Gaal LF (2008) Autoimmune gastritis in type 1 diabetes: a clinically oriented review. J Clin Endocrinol Metab 93(2):363–371PubMedCrossRef

48.

Korstanje A, den Hartog G, Biemond I, Lamers CB (2002) The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature. Scand J Gastroenterol (236):22–26.

49.

Iijima K, Abe Y, Kikuchi R, Koike T, Ohara S, Sipponen P, Shimosegawa T (2009) Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol 15(7):853–859PubMedCrossRef

50.

Korstanje A, van Eeden S, Offerhaus JA, Waltman FL, Hartog G, Roelandse FW, Souverijn JH, Biemond I, Lamers CB (2008) Comparison between serology and histology in the diagnosis of advanced gastric body atrophy: a study in a Dutch primary community. J Clin Gastroenterol 42(1):18–22PubMedCrossRef

51.

Checchi S, Montanaro A, Pasqui L, Ciuoli C, Cevenini G, Sestini F, Fioravanti C, Pacini F (2007) Serum ghrelin as a marker of atrophic body gastritis in patients with parietal cell antibodies. J Clin Endocrinol Metab 92(11):4346–4351PubMedCrossRef

52.

Suzuki H, Masaoka T, Hosoda H, Nomura S, Ohara T, Kangawa K, Ishii H, Hibi T (2004) Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio—a possible novel and non-invasive marker for gastric atrophy. Hepatogastroenterology 51(59):1249–1254PubMed

53.

Kawashima J, Ohno S, Sakurada T, Takabayashi H, Kudo M, Ro S, Kato S, Yakabi K (2009) Circulating acylated ghrelin level decreases in accordance with the extent of atrophic gastritis. J Gastroenterol 44(10):1046–1054PubMedCrossRef

54.

Chuang JS, Callaghan JM, Gleeson PA, Toh BH (1992) Diagnostic ELISA for parietal cell autoantibody using tomato lectin-purified gastric H+/K(+)-ATPase (proton pump). Autoimmunity 12(1):1–7PubMedCrossRef

55.

Sugiu K, Kamada T, Ito M, Kaya S, Tanaka A, Kusunoki H, Hata J, Haruma K (2006) Evaluation of an ELISA for detection of anti-parietal cell antibody. Hepatogastroenterology 53(67):11–14PubMed

56.

Lahner E, Norman GL, Severi C, Encabo S, Shums Z, Vannella L, Delle Fave G, Annibale B (2009) Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol 104(8):2071–2079PubMedCrossRef

57.

Khan S, Del-Duca C, Fenton E, Holding S, Hirst J, Doré PC, Sewell WA (2009) Limited value of testing for intrinsic factor antibodies with negative gastric parietal cell antibodies in pernicious anaemia. J Clin Pathol 62(5):439–441PubMedCrossRef

58.

Tozzoli R, Kodermaz G, Perosa AR, Tampoia M, Zucano A, Antico A, Bizzaro N (2010) Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases. Autoimmun Rev (in press)

59.

Alonso N, Granada ML, Soldevila B, Salinas I, Joaquin C, Reverter JL, Juncà J, Martínez Cáceres EM, Sanmartí A (2010) Serum autoimmune gastritis markers, pepsinogen 1 and parietal cell antibodies in patients with type 1 diabetes mellitus. A 5 year prospective study. J Endocrinol Invest (in press)

60.

Biondo M, Field J, Toh BH, Alderuccio F (2006) Prednisolone promotes remission and gastric mucosal regeneration in experimental autoimmune gastritis. J Pathol 209(3):384–391PubMedCrossRef

61.

Marmont AM (2008) Will hematopoietic stem cell transplantation cure human autoimmune diseases? J Autoimmun 30(3):145–150PubMedCrossRef

62.

French MB, Allison J, Cram DS, Thomas HE, Dempsey-Collier M, Silva A, Georgiou HM, Kay TW, Harrison LC, Lew AM (1997) Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 46(1):34–39, Erratum in: Diabetes 1997 May;46(5):924PubMedCrossRef

63.

Chan J, Ban EJ, Chun KH, Wang S, Bäckström BT, Bernard CC, Toh BH, Alderuccio F (2008) Transplantation of bone marrow transduced to express self-antigen establishes deletional tolerance and permanently remits autoimmune disease. J Immunol 181(11):7571–7580PubMed

64.

Xu B, Haviernik P, Wolfraim LA, Bunting KD, Scott DW (2006) Bone marrow transplantation combined with gene therapy to induce antigen-specific tolerance and ameliorate EAE. Mol Ther 13(1):42–48PubMedCrossRef

65.

Alderuccio F, Chan J, Ko HJ, Chung JY, Nasa Z, Toh BH (2010) A molecular Trojan horse: hijacking the bone marrow to treat autoimmune diseases. Discov Med 49:512–518, PubMed PMID: 20587340

66.

Alderuccio F, Chan J, Scott DW, Toh BH (2009) Gene therapy and bone marrow stem-cell transfer to treat autoimmune disease. Trends Mol Med 15(8):344–351PubMedCrossRef

Title: Cutting Edge Issues in Autoimmune Gastritis
Authors: Ban-Hock Toh
James Chan
Tin Kyaw
Frank Alderuccio
Publication date: 01-06-2012
Publisher: Humana Press Inc
Published in: Clinical Reviews in Allergy & Immunology / Issue 3/2012
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-010-8218-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Cutting Edge Issues in Autoimmune Hepatitis

Cutting-Edge Issues in Celiac Disease and in Gluten Intolerance

Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature

Cutting-edge Issues in Autoimmunity and Allergy of the Digestive System

Cutting-Edge Issues in Primary Biliary Cirrhosis

A Novel Algorithm for the Diagnosis of Celiac Disease and a Comprehensive Review of Celiac Disease Diagnostics

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials